|
1
|
Peto J, Decarli A, La Vecchia C, Levi F
and Negri E: The European mesothelioma epidemic. Br J Cancer.
79:666–672. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Price B: Analysis of current trends in
United States mesothelioma incidence. Am J Epidemiol. 145:211–218.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hodgson JT, McElvenny DM, Darnton AJ,
Price MJ and Peto J: The expected burden of mesothelioma mortality
in Great Britan from 2002 to 2050. Br J Cancer. 92:587–593.
2005.PubMed/NCBI
|
|
4
|
McCormack V, Peto J, Byrnes G, Straif K
and Boffetta P: Estimating the asbestos-related lung cancer burden
from mesothelioma mortality. Br J Cancer. 106:575–584. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Van Ruth S, Bass P and Zoetmulder FA:
Surgical treatment of malignant pleural mesothelioma: a review.
Chest. 123:551–561. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Treasure T, Lang-Lazdunski L, Waller D,
Bliss JM, Tan C, Entwisle J, Snee M, O’Brien M, Thomas G, Senan S,
O’Byrne K, Kilburn LS, Spicer J, Landau D, Edwards J, Coombes G,
Darlison L and Peto J; for the MarS trialists. Extra-pleural
pneumonectomy versus no extra-pleural pneumonectomy for patients
with malignant pleural mesothelioma: clinical outcomes of the
mesothelioma and radical surgery (MARS) randomized feasibility
study. Lancet Oncol. 12:763–772. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pass HI, Kranda K, Temeck BK, Feuerstein I
and Steinberg SM: Surgically debulked malignant pleural
mesothelioma: results and prognostic factors. Ann Surg Oncol.
4:215–222. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Krug LM, Pass HI, Rusch VW, Kindler HL,
Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K,
Monberg M, Obasaju CK and Vogelzang NJ: Multicenter phase II trial
of neoadjuvant pemetrexed plus cisplatin followed by extrapleural
pneumonectomy and radiation for malignant pleural mesothelioma. J
Clin Oncol. 27:3007–3013. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Adjei AA: Pemetrexed (ALIMTA), a novel
multitargeted anti-neoplastic agent. Clin Cancer Res.
10:4276s–4280s. 2004. View Article : Google Scholar
|
|
10
|
Vogelzang NJ, Porta C and Mutti L: New
agents in the management of advanced mesothelioma. Semin Oncol.
32:336–350. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S,
Maneqold C, Niyikiza C and Paoletti P: Phase III study of
pemetrexed in combination with cisplatin versus cisplatin alone in
patients with malignant pleural mesothelioma. J Clin Oncol.
21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rea F, Marulli G, Bortolotti L, Breda C,
Favaretto AG, Loreggian L and Sartori F: Induction chemotherapy,
extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic
radiation in malignant pleural mesothelioma (MPM): Feasibility and
results. Lung Cancer. 57:89–95. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Flores RM, Pass HI, Seshan VE, Dycoco J,
Zakowski M, Carbone M, Bains MS and Rusch VW: Extrapleural
pneumonectomy versus pleurectomy/decortication in the surgical
management of malignant mesothelioma: results in 663 patients. J
Thorac Cardiovasc Surg. 135:620–626. 2008. View Article : Google Scholar
|
|
14
|
Dougherty TJ, Gomer CJ, Henderson BW, et
al: Photodynamic therapy. J Natl Cancer Inst. 90:889–905. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dougherty TJ: An update on photodynamic
therapy applications. J Clin Laser Med Surg. 20:3–7. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Edell ES and Cortese DA: Photodynamic
therapy in the management of early superficial squamous cell
carcinoma as an alternative to surgical resection. Chest.
102:1319–1322. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kato H, Usuda J, Okunaka T, Furukawa K,
Honda H, Sakaniwa N, Suga Y, Hirata T, Ohtani K, Inoue T, Maehara
S, Kubota M, Yamada K and Tsuitsui H: Basic and clinical research
on photodynamic therapy at Tokyo Medical University Hospital.
Lasers Surg Med. 38:371–375. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kennedy TC, McWilliams A, Edell E, Sutedja
T, Downie G, Yung R, Gazdar A and Mahur PN; American College of
Chest Physicians. Bronchial intraepithelial neoplasia/early central
airways lung cancer: ACCP evidence-based clinical practice
guidelines (2nd edition). Chest. 132(Suppl 3): S221–S233. 2007.
View Article : Google Scholar
|
|
19
|
Krueger T, Altermatt HJ, Mettler D, Scholl
B, Magnusson L and Ris HB: Experimental photodynamic therapy for
malignant pleural mesothelioma with pegylated mTHPC. Laser Surg
Med. 32:61–68. 2003. View Article : Google Scholar
|
|
20
|
Friedberg JS, Mick R, Stevenson J, Metz J,
Zhu T, Buyske J, Sterman DH, Pass HI, Glatstein E and Hahn SM: A
phase I study of Foscan-mediated photodynamic therapy and surgery
in patients with mesothelioma. Ann Thorac Surg. 75:952–959. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ris HB: Photodynamic therapy as an adjunct
to surgery for malignant pleural mesothelioma. Lung Cancer.
49(Suppl 1): S65–S68. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pass HI, Temeck BK, Kranda K, Thomas G,
Russo A, Smith P, Friauf W and Steinberg SM: Phase III randomized
trial of surgery with or without intraoperative photodynamic
therapy and postoperative immunochemotherapy for malignant pleural
mesothelioma. Ann Surg Oncol. 4:628–633. 1997. View Article : Google Scholar
|
|
23
|
Usuda J, Ichinose S, Ishizumi T, Hayashi
H, Ohtani K, Maehara S, Ono S, Honda H, Kajiwara N, Uchida O,
Tsutsui H, Ohira T, Kato H and Ikeda N: Outcome of photodynamic
therapy using NPe6 for bronchogenic carcinomas in central airways
>1.0 cm in diameter. Clin Cancer Res. 16:2198–2204. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ozasa H, Oguri T, Uemura T, Miyazaki M,
Maeno K, Sato S and Ueda R: Significance of thymidylate synthase
for resistance to pemetrexed in lung cancer. Cancer Sci.
101:161–166. 2010. View Article : Google Scholar
|
|
25
|
O’Kane SL, Eagle GL, Greenman J, Lind MJ
and Gawkwell L: COX-2 specific inhibitors enhance the cytotoxic
effects of pemetrexed in mesothelioma cell lines. Lung Cancer.
67:160–165. 2010. View Article : Google Scholar
|
|
26
|
Usuda J, Chiu SM, Murphy ES, Lam M,
Nieminen AL and Oleinick NL: Domain-dependent photodamage to Bcl-2.
A membrane anchorage region is needed to form the target of
phthalocyanine photosensitization. J Biol Chem. 278:2021–2029.
2003. View Article : Google Scholar
|
|
27
|
Usuda J, Hirata T, Ichinose S, Ishizumi T,
Inoue T, Ohtani K, Maehara S, Yamada M, Tsutsui H, Okunaka T, Kato
H and Ikeda N: Tailor-made approach to photodynamic therapy in the
treatment of cancer based on Bcl-2 photodamage. Int J Oncol.
33:689–696. 2008.PubMed/NCBI
|
|
28
|
Kato H, Furukawa K, Sato M, Okunaka T,
Kusunoki Y, Kawahara M, et al: Phase II clinical study of
photodynamic therapy using mono-L-aspartyl chlorine e6 and diode
laser for early superficial squamous cell carcinoma of the lung.
Lung Cancer. 42:103–111. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Usuda J, Tsunoda Y, Ichinose S, Ishizumi
T, Ohtani K, Maehara S, Ono S, Tsutsui H, Ohira T, Okunaka T,
Furukawa K, Sugimoto Y, Kato H and Ikeda N: Breast cancer resistant
protein (BCRP) is a molecular determinant of the outcome of
photodynamic therapy (PDT) for centrally located early lung cancer.
Lung Cancer. 67:198–204. 2010. View Article : Google Scholar
|
|
30
|
Xue LY, Chiu SM and Oleinick NL:
Photodynamic therapy-induced death of MCF-7 human breast cancer
cells: a role for caspase-3 in the late steps of apoptosis but not
for the critical lethal event. Exp Cell Res. 263:145–155. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Workman P, Aboagye EO, Balkwill F, Balmain
A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA,
Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson
S, Wedge SR and Eccles SA; Committee of the National Cancer
Research Institute. Guidelines for the welfare and use of animals
in cancer research. Br J Cancer. 102:1555–1577. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ohtani K, Usuda J, Ichinose S, Ishizumi T,
Hirata T, et al: High expression of GADD-45α and VEGF induced tumor
recurrence via upregulation of IL-2 after photodynamic therapy
using NPe6. Int J Oncol. 32:397–403. 2008.PubMed/NCBI
|
|
33
|
Van TT, Hanibuchi M, Kakiuchi S, Sato S,
Kuramoto T, Goto H, Mitsuhashi A, Nishioka Y, Akiyama S and Sone S:
The therapeutic efficacy of S-1 against orthotopically implanted
human pleural mesothelioma cells in severe combined immunodeficient
mice. Cancer Chemother Pharmacol. 68:497–504. 2011. View Article : Google Scholar :
|
|
34
|
Cappia S, Righi L, Mirabelli D, Ceppi P,
Bacillo E, Ardissone F, Molinaro L, Scagliotti GV and Papotti M:
Prognostic role of osteopontin expression in malignant pleural
mesothelioma. Am J Clin Pathol. 130:58–64. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Righi L, Papotti MG, Ceppi P, Bille A,
Bacillo E, Molinaro L, Ruffini E, Scagliotti GV and Selvaggi G:
Thymidylate synthase but not excision repair cross-complementation
group 1 tumor expression predicts outcome in patients with
malignant pleural mesothelioma treated with pemetrexed-based
chemotherapy. J Clin Oncol. 28:1534–1539. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Debefve E, Mithieux F, Perentes JY, Wang
Y, Cheng C, Schaefer SC, Ruffieux C, Ballini JP, Gonzalez M, van
den Bergh H, Ris HB, Lehr HA and Krueger T: Leukocyte-endothelial
cell interaction is necessary for photodynamic therapy induced
vascular permeabilization. Lasers Surg Med. 43:696–704.
2011.PubMed/NCBI
|
|
37
|
Snyder JW, Greco WR, Bellnier DA, Vaughan
L and Henderson BW: Photodynamic therapy: a means to enhanced drug
delivery to tumors. Cancer Res. 63:8126–8131. 2003.PubMed/NCBI
|
|
38
|
Wang Y, Perentes JY, Schäfer SC, Gonzalez
M, Debefve E, Lehr HA, van den Bergh H and Krueger T: Photodynamic
drug delivery enhancement in tumors does not depend on
leukocyte-endothelial interaction in a human mesothelioma xenograft
model. Eur J Cardiothorac Surg. 42:348–354. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sitnik TM, Hampton JA and Henderson BW:
Reduction of tumor oxygenation during and after photodynamic
therapy in vivo: effects of fluence rate. Br J Cancer.
77:1386–1394. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Oleinick NL, Morris RL and Belichenko I:
The role of apoptosis in response to photodynamic therapy: what,
where, why, and how. Photochem photobiol Sci. 1:1–21. 2002.
View Article : Google Scholar
|
|
41
|
Robey RW, Steadman K, Polgar O and Bates
SE: ABCG2-mediated transport of photosensitizers: potential impact
on photodynamic therapy. Cancer Biol Ther. 4:187–194. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Anand S, Honari G, Hasan T, Elson P and
Maytin EV: Low-dose methotrexate enhances aminolevulinate-based
photodynamic therapy in skin carcinoma cells in vitro and in vivo.
Clin Cancer Res. 15:3333–3343. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sinha AK, Anand S, Ortel BJ, Chang Y, Mai
Z, Hasan T and Maytin EV: Methotrexate used in combination with
aminolaevulinic acid for photodynamic killing of prostate cancer
cells. Br J Cancer. 95:485–495. 2006. View Article : Google Scholar : PubMed/NCBI
|
